Fang He1, Wei Luo, Qun Zhang, Ying Guo, Meng-zhong Liu, Jun Ma. 1. Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center,Guangzhou 510060, China.
Abstract
OBJECTIVE: To analyze the effectiveness and toxicity of intensity-modulated radiotherapy (IMRT) combined with chemotherapy or not for locoregionally advanced nasopharyngeal carcinoma. METHODS: A total of 226 patients with locoregionally advanced nasopharyngeal carcinoma were retrospectively reviewed and classified into three groups:67 patients treated by radiotherapy alone (RT group), 82 patients by concurrent chemoradiotherapy (CRT group) and 77 patients by cisplatin+5-fluorouracil (PF regimen) combined with CRT (PF+CRT group). All patients using IMRT technique.Outcomes were overall survival, failure patterns, and toxicities. RESULTS: For the RT, CRT and PF+CRT group, the 5-year overall survival rate was 67.6%, 74% and 71.1% (P = 0.664), respectively; progress-free survival rate 66.9%, 72.6% and 75.6% (P = 0.410); relapse-free survival rate 82.4%, 86.4% and 86.8% (P = 0.447) and distant metastasis-free survival rate 83.8%, 83.8% and 85.8% (P = 0.827). Significantly more grade 3-4 acute toxicities happened in patients treated by chemotherapy (P = 0.002). CONCLUSION: Comparing with IMRT alone, cisplatin-IMRT or PF regimen induction chemotherapy plus cisplatin-IMRT do not significantly improve survival, but increased grade 3-4 acute toxicities.
OBJECTIVE: To analyze the effectiveness and toxicity of intensity-modulated radiotherapy (IMRT) combined with chemotherapy or not for locoregionally advanced nasopharyngeal carcinoma. METHODS: A total of 226 patients with locoregionally advanced nasopharyngeal carcinoma were retrospectively reviewed and classified into three groups:67 patients treated by radiotherapy alone (RT group), 82 patients by concurrent chemoradiotherapy (CRT group) and 77 patients by cisplatin+5-fluorouracil (PF regimen) combined with CRT (PF+CRT group). All patients using IMRT technique.Outcomes were overall survival, failure patterns, and toxicities. RESULTS: For the RT, CRT and PF+CRT group, the 5-year overall survival rate was 67.6%, 74% and 71.1% (P = 0.664), respectively; progress-free survival rate 66.9%, 72.6% and 75.6% (P = 0.410); relapse-free survival rate 82.4%, 86.4% and 86.8% (P = 0.447) and distant metastasis-free survival rate 83.8%, 83.8% and 85.8% (P = 0.827). Significantly more grade 3-4 acute toxicities happened in patients treated by chemotherapy (P = 0.002). CONCLUSION: Comparing with IMRT alone, cisplatin-IMRT or PF regimen induction chemotherapy plus cisplatin-IMRT do not significantly improve survival, but increased grade 3-4 acute toxicities.